006280.KO Green Cross Corp
- Market cap
- KRW 1.62T
- P/E
- -
- P/B
- 1.28x
- ROE
- 3.6%
- Dividend yield
- 1.16%
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 2 quarters up to Jun 2026.
Is 006280.KO undervalued?
Graham numberThe Graham number of Green Cross Corp cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Green Cross Corp fundamental analysis
No fundamental analysis for Green Cross Corp yet.
Green Cross Corp stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Green Cross Corp
GC Biopharma Corp., a biopharmaceutical company, develops and sells pharmaceutical drugs in South Korea, India, Taiwan, Japan, China, Malaysia, and internationally. It provides over-the-counter drugs, such as Acustop Cataplasma for Analgesic and anti-inflammatory effect; Kenhancer plaster for anti-inflammatory; and Zenol Cool Type and Zenol Mild Hot Type drugs to treat anti-inflammatory and pain relief. The company also offers Albumin-GCC injection (inj.) for hypoalbuminemia…
Full company profileGreen Cross Corp financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 2 quarters up to Jun 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Green Cross Corp annual financial statements (KRW; K = thousand, M = million, B = billion, T = trillion)
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||
| Revenue | 1.20T | 1.29T | 1.33T | 1.37T | 1.50T | 1.54T | 1.71T | 1.63T | 1.68T | 1.99T | 1.71T |
| Gross Profit | 352B | 367B | 346B | 372B | 441B | 521B | 582B | 485B | 482B | 554B | 465B |
| Operating Income | 78.5B | 90.3B | 50.2B | 40.3B | 50.3B | 73.7B | 81.3B | 34.4B | 32.1B | 69.1B | 26.9B |
| EBITDA | - | 115B | 97.9B | 50.1B | 164B | 241B | 169B | 77.2B | 80.4B | 103B | 191B |
| Net Income | 63.0B | 53.2B | 34.4B | -3.64B | 81.0B | 123B | 65.5B | -26.6B | -26.3B | -4.67B | 44.9B |
| EPS | - | 4,665 | 3,017 | -319 | 7,101 | 10,796 | 5,735 | -2,333 | -2,303 | -410 | 3,935 |
| Balance Sheet | |||||||||||
| Total Assets | 1.55T | 1.70T | 1.72T | 1.96T | 2.15T | 2.46T | 2.53T | 2.64T | 2.74T | 2.97T | 2.82T |
| Total Liabilities | 492B | 595B | 597B | 775B | 882B | 962B | 959B | 1.10T | 1.26T | 1.58T | 1.49T |
| Shareholders' Equity | 993B | 1.04T | 1.06T | 1.05T | 1.12T | 1.27T | 1.33T | 1.30T | 1.25T | 1.22T | 1.24T |
| Cash & Short-term Investments | 56.9B | 171B | 96.6B | 98.5B | 232B | 186B | 105B | 49.7B | 22.6B | 49.4B | 41.7B |
| Cash Flow | |||||||||||
| Operating Cash Flow | -1.74B | 57.9B | 14.4B | 40.3B | 36.0B | 126B | 119B | -5.47B | -53.5B | 99.5B | -9.51B |
| Capital Expenditure | 98.7B | 29.5B | 41.4B | 127B | 82.9B | 102B | 94.7B | 126B | 42.4B | 105B | 113B |
| Free Cash Flow | - | 2.31B | -50.6B | -107B | -65.4B | 2.44B | 24.5B | -131B | -95.9B | -5.82B | -122B |
| Ratios | |||||||||||
| ROE | 6.3% | 5.1% | 3.2% | -0.3% | 7.2% | 9.7% | 4.9% | -2.0% | -2.1% | -0.4% | 3.6% |
| ROA | 4.1% | 3.1% | 2.0% | -0.2% | 3.8% | 5.0% | 2.6% | -1.0% | -1.0% | -0.2% | 1.6% |
| Net Profit Margin | 5.3% | 4.1% | 2.6% | -0.3% | 5.4% | 8.0% | 3.8% | -1.6% | -1.6% | -0.2% | 2.6% |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
Green Cross Corp dividends
- Dividend yield
- 1.16%
- Forward dividend
- 1,500.00 KRW
- Payout ratio
- -
- Ex-dividend date
- Mar 30, 2026
| Fiscal year | Dividends paid | Per share | Payout ratio |
|---|---|---|---|
| 2025 | KRW 18.8B | 1,650 | - |
| 2024 | KRW 19.5B | 1,711 | - |
| 2023 | KRW 24.8B | 2,175 | - |
| 2022 | KRW 24.0B | 2,102 | 36.6% |
| 2021 | KRW 18.5B | 1,622 | 15.0% |
| 2020 | KRW 12.7B | 1,114 | 15.7% |
| 2019 | KRW 12.4B | 1,085 | - |
| 2018 | KRW 15.3B | 1,343 | 44.5% |
| 2017 | KRW 15.3B | 1,343 | 28.8% |
From the cash flow statement: dividends paid in the fiscal year, divided by that year's shares outstanding. Payout ratio = dividends paid / net income.
Last stock split: 1.05:1 on Jun 7, 2013.
Who owns Green Cross Corp
- Insiders 51.44%
- Institutions 15.14%
- Public & others 33.42%
- Shares outstanding 11.4M
- Free float 5.45M
Green Cross Corp company profile
- Company name
- Green Cross Corp
- Ticker
- 006280.KO
- ISIN
- KR7006280002
- Exchange
- Korea Stock Exchange
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 2,111
- Fiscal year end
- December
- Address
- 107, Ihyeon-ro 30beon-gil, Yongin-Si, South Korea
- Phone
- 82 3 1260 9300
- Website
- gcbiopharma.com
About Green Cross Corp
GC Biopharma Corp., a biopharmaceutical company, develops and sells pharmaceutical drugs in South Korea, India, Taiwan, Japan, China, Malaysia, and internationally. It provides over-the-counter drugs, such as Acustop Cataplasma for Analgesic and anti-inflammatory effect; Kenhancer plaster for anti-inflammatory; and Zenol Cool Type and Zenol Mild Hot Type drugs to treat anti-inflammatory and pain relief. The company also offers Albumin-GCC injection (inj.) for hypoalbuminemia and shock in acute hemorrhage, as well as low synthesis of albumin; Antithrombin-III (AT-III) inj. for hereditary antithrombin-III deficiency; Facnyne inj. for hemophilia B; Fibrinogen to treat hypofibrinogenemia and afibrinogenemia; Gamma Globulin for hypogammaglobulinemia and agammaglobulinemia; GCFLU Quadrivalent and GC FLU pre-filled syringe inj. for prevention of influenza; GreenGene F inj. for bleeding symptom control and hemostasis for persons with hemophilia A; GreenGene inj. for bleeding episodes induced by hemophilia A; Greenplast Q for sealing tissues and closing open wounds; and Green-VIII inj. for Hemophilia A with supplies of blood coagulation factor VIII. In addition, it provides Hepabig inj. for hepatitis B; Histobulin to treat bronchial asthma; Hunterase for hunter syndrome; I.V. Hepabig inj. for prevention of hepatitis B recurrence in patients following liver transplantation; I.V.-Globulin SN inj. 5%; Immuncell-LC to treat liver cancer; Sero-Tet inj. for prophylaxis of tetanus and the reduction of tetanus symptoms; Shinbaro for anti-inflammation, pain relief, and osteoarthritis; and Varicella Vaccin. It has a research and development agreement with Novelty Nobility to develop antibody-based therapeutics for geographic atrophy. The company was founded in 1967 and is headquartered in Yongin-Si, South Korea. GC Biopharma Corp. operates as a subsidiary of Green Cross Holdings Corporation.
Green Cross Corp management
6- Mr. Eun-chul HuhCEO, President & Chairman · born 1972
- Mr. Woong Shin M.S.Head of Operations Division & Director
- Mr. Sean ZamHead of Sales & Marketing
- Mr. Young Sup HuhExecutive Vice President · born 1941
- Mr. In-Jae LeeSenior MD · born 1963
- Mr. Jae-Wook Jeong Ph.D.Head of Research and Development & Director